Matters of legal in nature including licensing, intellectual property, and lawsuits.
BILLERICA, Mass., Feb. 21, 2018 /PRNewswire/ — Bruker Corporation (NASDAQ: BRKR) today announced that Mr. Anthony L. Mattacchione, Chief Financial Officer (CFO) and Senior Vice President of Bruker, has submitted his resignation, effective as of March 16, 2018, in order to pursue other interests. Mr. Mattacchione has informed us that he has accepted a position as Chief... Read more
Location: Cambridge 12/02/2018 Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies demonstrating Horizon’s ability to generate revenues from internally derived IP Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic... Read more
MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) announced today that the U.S. International Trade Commission (the “ITC”) has terminated its investigation into whether Oxford Nanopore’s MinION and PromethION devices and associated consumables, reagents, and software infringe one or more claims of U.S. Patent Nos. 9,404,146 and 9,542,527, owned... Read more
Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Astrocytes iCell Cardiac Progenitor Cells iCell Cardiomyocytes iCell Cardiomyocytes2 iCell DopaNeurons iCell Endothelial Cells iCell GABANeurons iCell GlutaNeurons iCell Hematopoietic Progenitor Cells iCell Hepatoblasts iCell Hepatocytes... Read more
Thu 8th February 2018 In November 2016, PacBio filed a Complaint with the International Trade Commission (“ITC”) alleging that Oxford Nanopore infringed two of PacBio’s patents and seeking to prevent Oxford Nanopore from selling its product in the United States. Today, the ITC Commission has made a Final Determination affirming the Administrative Judge’s decision that... Read more
Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more
Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more
Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR... Read more
LOS ANGELES, Feb. 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new LA County program to help ensure proper containment and disposal of household sharps, a health concern that when disposed of improperly could cause injury or spread infection according to the U.S. Food... Read more
Sphere Fluidics Files US Patent on Novel Single Cell Encapsulation Biochip taking Patent Portfolio to 76 Filed Patents. by Sphere Fluidics | Jan 29, 2018 | News Read more